NCT00849732View on ClinicalTrials.gov

A Worldwide, Phase I, Dose-Escalating Study of a 3-Dose Regimen of the MRKAd5 (Clade B) Vaccine in Healthy Adults (V520-018)

PHASE1CompletedINTERVENTIONAL
Enrollment

360

Participants

Timeline

Start Date

June 30, 2003

Primary Completion Date

October 31, 2006

Study Completion Date

February 28, 2011

Conditions
HIV-1HIV Infections
Interventions
BIOLOGICAL

V520

Intentionally Blank

BIOLOGICAL

Comparator: V520 (1x10^9 vp/d)

1.0 mL intramuscular injection of MRKAd5 HIV-1 gag vaccine at 1x10\^9 vp/d given at Day 1, Week 4, and Week 26

BIOLOGICAL

Comparator: V520 (1x10^10 vp/d)

1.0 mL intramuscular injection of MRKAd5 HIV-1 gag vaccine at 1x10\^10 vp/d given at Day 1, Week 4, and Week 26

BIOLOGICAL

Comparator: Placebo

Placebo to MRKAd5 HIV-1 gag vaccine 1.0 mL intramuscular injection given at Day 1, Week 4, and Week 26

All Listed Sponsors
collaborator

HIV Vaccine Trials Network

NETWORK

collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00849732 - A Worldwide, Phase I, Dose-Escalating Study of a 3-Dose Regimen of the MRKAd5 (Clade B) Vaccine in Healthy Adults (V520-018) | Biotech Hunter | Biotech Hunter